- Boehringer Ingelheim licenses HIV candidate from P&U
- Boehringer Ingelheim licenses Medivir HIV candidate
- Roche, Trimeris in $88mm HIV drug development pact
- GSK gets rights to Medivir's HIV compounds; ends deal
- Medivir licenses MV026048 to Roche
- Zeneca acquires Astra for $31bn
- Medivir licenses HIV compound to Chiron; terminated
- Medivir, Chiron in hepatitis C deal
- Galderma licenses PhotoCure's cancer treatment
- Segulah buys Medivir's CCS AB skin care business
- Medivir, Paradigm develop protease inhibitors
- Peptide Therapeutics to generate leads for Peptimmune
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.